HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Hematologic malignancies in particular have responded well to treatment by HDAC inhibitors, such that vorinostat and romidepsin have been approved by the Federal Drug Administration (FDA) for treatment of refractory and advanced cutaneous T-cell lymphoma (CTCL) [11, 12].